Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 12 de septiembre del 2006
(September 11, 2006, Philadelphia, PA) The newly appointed Director of the Abramson Cancer Center of the University of Pennsylvania , Craig B. Thompson, MD, has named Caryn Lerman, PhD, Deputy Director, and Joseph R. Carver, MD, Chief of Staff . The appointments of Lerman, Carver, and Thompson provide a leadership team that will allow the Abramson Cancer Center to maintain its position as one of the top five Comprehensive Cancer Centers in National Cancer Institute funding. Together they will oversee 300 active cancer researchers and 299 full-time Penn physicians and faculty from eight Schools and 41 Departments across the University involved in research in cancer prevention, diagnosis, treatment, and survivorship. They will be responsible for $180 million in grant funding for cancer research and training, including $83.4 million in NCI funding.
Lerman joined Penn in 2001 as Mary W. Calkins Professor in the Department of Psychiatry of the School of Medicine and the Annenberg Public Policy Center. For the last five years, Lerman has served as Director of the Transdisciplinary Tobacco Use Research Center at Penn and Director of Cancer Control and Population Sciences in the Abramson Family Cancer Research Institute, the basic science core of the Abramson Cancer Center.
Following graduation from Pennsylvania State University, Lerman received her Doctorate in Clinical Psychology from USC and undertook clinical training at the Boston Veterans Administration Medical Center. She served on the faculty of the Medical College of Pennsylvania and Temple University School of Medicine. In 1993, Lerman was recruited to the Lombardi Cancer Center of Georgetown University Medical Center where she directed the Cancer Control Research Program until she was recruited to Penn. Lerman has been a member of the Board of Scientific Advisors of the NCI, and the National Human Genome Research (ELSI) Evaluation and Planning Review Committee. She has authored over 200 scientific papers on genetic susceptibility testing for cancer and nicotine dependence pharmacogenetics, and has received awards for her scholarship from the National Cancer Institute, the American Psychological Association and the American Society of Preventive Oncology.
Carver has been a Clinical Professor of Medicine at Penn since 2003. He currently serves as the Senior Administrative Officer of the Abramson Family Cancer Research Institute and is a member of the Division of Cardiology. He will continue to hold both of these positions while serving as the Chief of Staff of the Abramson Cancer Center.
A graduate of Temple University, Carver undertook his medical training at Hahnemann University School of Medicine. In the past he has served on the staffs of Hahnemann, Jeanes Hospital and the American Oncologic Hospital. For the 10 years prior to joining Penn, Carver served as a Corporate Medical Director for Aetna U.S. Healthcare.
Carver brings extensive administrative experience to the Abramson Cancer Center having served on the Board of Directors of numerous for-profit and non-profit organizations. He has served on the Board of Overseers of Penn's Nursing School and recently helped lead the Cancer Cardiovascular Survivors Guidelines Taskforce for the American Society of Clinical Oncology. Carver has authored over 75 medical papers and monographs and last year received the Distinguished Teacher Award in Cardiology from the School of Medicine. His expertise in the treatment of cardiac disease during cancer therapy has won him national recognition.
Joining the Abramson Cancer Centers new administrative team is Mr. Robert F. Wynne . Wynne will join the Center as the Director of Financial and Administrative Affairs. In this new position, he will provide financial oversight over the combined activities of the Abramson Cancer Center and the Department of Cancer Biology. A graduate of Cornell University, Wynne joins the ACC management team having served previously as the Business Administrator for the Department of Cancer Biology and the Director of Fiscal and Administrative Operations in the Abramson Family Cancer Research Institute. Prior to that he, served as Business Administrator of Hematology/Oncology in the Department of Medicine.
CONTACT: Olivia Fermano
(215) 349-5653
olivia.fermano@uphs.upenn.edu
PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals [Hospital of the University of Pennsylvania, which is consistently ranked one of the nation's few "Honor Roll" hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.
About the Abramson Cancer Center: The Abramson Cancer Center of the University of Pennsylvania was established in 1973 as a center of excellence in cancer research, patient care, education and outreach. Today, the Abramson Cancer Center ranks as one of the nation's best in cancer care, according to U.S. News and World Report, and is one of the top five in National Cancer Institute (NCI) funding. It is one of only 39 NCI-designated comprehensive cancer centers in the United States. Home to one of the largest clinical and research programs in the world, the Abramson Cancer Center of the University of Pennsylvania has 300 active cancer researchers and 299 Penn physicians involved in cancer prevention, diagnosis and treatment. More information about the Abramson Cancer Center is available at: www.pennhealth.com/cancer
Dr. Mao talks about complementary and alternative medicine and the importance of being open about their use with cancer caregivers. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

